Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice

Witold Lasek, Anna Wańkowicz, Katarzyna Kuc, Wojciech Feleszko, Jakub Golab, Adam Giermasz, Wieslaw Wiktor-J/cedrzejczak, Marek Jakóbisiak

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The efficacy of systemic infusion of recombinant human macrophage-colony-stimulating factor (M-CSF) in combination with local treatment with human recombinant tumor necrosis factor (TNF) α and mouse recombinant interferon (IFN) γ was studied in vivo on a subclone of B16 melanoma (MmB16) in mice. Short-term intravenous administration of M-CSF at a dose of 106 units daily had no antitumor effect in vivo. Similarly, local treatment of tumor with TNFα (5 μg daily) did not produce any therapeutic effect. However, simultaneous administration of the same dose of TNFα with IFNγ (1000 units daily) resulted in a synergistic effects manifested by the retardation of tumor growth. Addition of systemic infusion of M-CSF to the local therapy with TNFα and IFNγ induced further augmentation of antitumor efficacy and delayed progression of MmB16 melanoma. The strengthened antitumor effect of combination therapy including M-CSF, TNFα and IFNγ was most probably due to the increased release of monocytes from the bone marrow, their recruitment into the site of tumor growth and subsequent local stimulation of their antitumor activity.

Original languageEnglish (US)
Pages (from-to)315-321
Number of pages7
JournalCancer Immunology Immunotherapy
Volume40
Issue number5
DOIs
StatePublished - Sep 1995
Externally publishedYes

Fingerprint

Macrophage Colony-Stimulating Factor
Interferons
Melanoma
Tumor Necrosis Factor-alpha
Neoplasms
Experimental Melanomas
Therapeutic Uses
Therapeutics
Growth
Intravenous Administration
Monocytes
Bone Marrow

Keywords

  • Interferon γ
  • Macrophage-colony-stimulating factor
  • Tumor immunotherapy
  • Tumor necrosis factor α

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. / Lasek, Witold; Wańkowicz, Anna; Kuc, Katarzyna; Feleszko, Wojciech; Golab, Jakub; Giermasz, Adam; Wiktor-J/cedrzejczak, Wieslaw; Jakóbisiak, Marek.

In: Cancer Immunology Immunotherapy, Vol. 40, No. 5, 09.1995, p. 315-321.

Research output: Contribution to journalArticle

Lasek, Witold ; Wańkowicz, Anna ; Kuc, Katarzyna ; Feleszko, Wojciech ; Golab, Jakub ; Giermasz, Adam ; Wiktor-J/cedrzejczak, Wieslaw ; Jakóbisiak, Marek. / Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice. In: Cancer Immunology Immunotherapy. 1995 ; Vol. 40, No. 5. pp. 315-321.
@article{ca20a95d7e5e418ba1359ba35b7f9d8d,
title = "Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice",
abstract = "The efficacy of systemic infusion of recombinant human macrophage-colony-stimulating factor (M-CSF) in combination with local treatment with human recombinant tumor necrosis factor (TNF) α and mouse recombinant interferon (IFN) γ was studied in vivo on a subclone of B16 melanoma (MmB16) in mice. Short-term intravenous administration of M-CSF at a dose of 106 units daily had no antitumor effect in vivo. Similarly, local treatment of tumor with TNFα (5 μg daily) did not produce any therapeutic effect. However, simultaneous administration of the same dose of TNFα with IFNγ (1000 units daily) resulted in a synergistic effects manifested by the retardation of tumor growth. Addition of systemic infusion of M-CSF to the local therapy with TNFα and IFNγ induced further augmentation of antitumor efficacy and delayed progression of MmB16 melanoma. The strengthened antitumor effect of combination therapy including M-CSF, TNFα and IFNγ was most probably due to the increased release of monocytes from the bone marrow, their recruitment into the site of tumor growth and subsequent local stimulation of their antitumor activity.",
keywords = "Interferon γ, Macrophage-colony-stimulating factor, Tumor immunotherapy, Tumor necrosis factor α",
author = "Witold Lasek and Anna Wańkowicz and Katarzyna Kuc and Wojciech Feleszko and Jakub Golab and Adam Giermasz and Wieslaw Wiktor-J/cedrzejczak and Marek Jak{\'o}bisiak",
year = "1995",
month = "9",
doi = "10.1007/BF01519632",
language = "English (US)",
volume = "40",
pages = "315--321",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "5",

}

TY - JOUR

T1 - Potentiation of antitumor effects of tumor necrosis factor α and interferon γ by macrophage-colony-stimulating factor in a MmB16 melanoma model in mice

AU - Lasek, Witold

AU - Wańkowicz, Anna

AU - Kuc, Katarzyna

AU - Feleszko, Wojciech

AU - Golab, Jakub

AU - Giermasz, Adam

AU - Wiktor-J/cedrzejczak, Wieslaw

AU - Jakóbisiak, Marek

PY - 1995/9

Y1 - 1995/9

N2 - The efficacy of systemic infusion of recombinant human macrophage-colony-stimulating factor (M-CSF) in combination with local treatment with human recombinant tumor necrosis factor (TNF) α and mouse recombinant interferon (IFN) γ was studied in vivo on a subclone of B16 melanoma (MmB16) in mice. Short-term intravenous administration of M-CSF at a dose of 106 units daily had no antitumor effect in vivo. Similarly, local treatment of tumor with TNFα (5 μg daily) did not produce any therapeutic effect. However, simultaneous administration of the same dose of TNFα with IFNγ (1000 units daily) resulted in a synergistic effects manifested by the retardation of tumor growth. Addition of systemic infusion of M-CSF to the local therapy with TNFα and IFNγ induced further augmentation of antitumor efficacy and delayed progression of MmB16 melanoma. The strengthened antitumor effect of combination therapy including M-CSF, TNFα and IFNγ was most probably due to the increased release of monocytes from the bone marrow, their recruitment into the site of tumor growth and subsequent local stimulation of their antitumor activity.

AB - The efficacy of systemic infusion of recombinant human macrophage-colony-stimulating factor (M-CSF) in combination with local treatment with human recombinant tumor necrosis factor (TNF) α and mouse recombinant interferon (IFN) γ was studied in vivo on a subclone of B16 melanoma (MmB16) in mice. Short-term intravenous administration of M-CSF at a dose of 106 units daily had no antitumor effect in vivo. Similarly, local treatment of tumor with TNFα (5 μg daily) did not produce any therapeutic effect. However, simultaneous administration of the same dose of TNFα with IFNγ (1000 units daily) resulted in a synergistic effects manifested by the retardation of tumor growth. Addition of systemic infusion of M-CSF to the local therapy with TNFα and IFNγ induced further augmentation of antitumor efficacy and delayed progression of MmB16 melanoma. The strengthened antitumor effect of combination therapy including M-CSF, TNFα and IFNγ was most probably due to the increased release of monocytes from the bone marrow, their recruitment into the site of tumor growth and subsequent local stimulation of their antitumor activity.

KW - Interferon γ

KW - Macrophage-colony-stimulating factor

KW - Tumor immunotherapy

KW - Tumor necrosis factor α

UR - http://www.scopus.com/inward/record.url?scp=0029039153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029039153&partnerID=8YFLogxK

U2 - 10.1007/BF01519632

DO - 10.1007/BF01519632

M3 - Article

C2 - 7600564

AN - SCOPUS:0029039153

VL - 40

SP - 315

EP - 321

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 5

ER -